# Candida Auris Spreads Across 23 U.S. States as Drug-Resistant Fungal Infection
The Centers for Disease Control and Prevention reports that Candida auris, a dangerous drug-resistant fungal infection, now appears in 23 states across the United States. This multidrug-resistant organism poses a serious public health threat, particularly in healthcare settings.
Candida auris differs from common yeast infections. The fungus resists multiple antifungal medications, leaving treatment options limited. It primarily affects hospitalized patients and those with weakened immune systems, though transmission between people remains possible in medical environments.
The CDC identifies several risk factors for infection. Prolonged hospital stays, invasive medical devices like catheters, and prior antibiotic or antifungal treatment increase vulnerability. The fungus can colonize skin and mucous membranes without causing immediate symptoms, making screening essential in high-risk populations.
Symptoms vary depending on infection location. Bloodstream infections trigger fever and chills. Wound infections produce localized inflammation and drainage. Respiratory infections cause cough and difficulty breathing. Death rates from invasive Candida auris infections reach 30 to 60 percent in some patient populations.
Healthcare facilities combat spread through rigorous infection control. The CDC recommends contact precautions, dedicated equipment, and frequent environmental cleaning with chlorine-based disinfectants. Healthcare workers must follow strict hand hygiene protocols. Some hospitals screen high-risk patients upon admission to identify colonization early.
Treatment relies on specific antifungal classes since the organism resists fluconazole and other azole drugs. Echinocandins like caspofungin or micafungin serve as first-line therapy. Amphotericin B remains an option for severe cases, though side effects limit long-